CA Patent

CA2965185A1 — Method and composition for treating ocular hypertension and glaucoma

Assigned to Santen Pharmaceutical Co Ltd · Expires 2009-12-03 · 16y expired

What this patent protects

The present invention relates to an ophthalmic aqueous composition containing PGF2.alpha. analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, …

USPTO Abstract

The present invention relates to an ophthalmic aqueous composition containing PGF2.alpha. analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2.alpha. analogues in an aqueous composition.

Drugs covered by this patent

Patent Metadata

Patent number
CA2965185A1
Jurisdiction
CA
Classification
Expires
2009-12-03
Drug substance claim
No
Drug product claim
No
Assignee
Santen Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.